IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary

IRIDEX CORP reported first-quarter 2026 results showing essentially flat revenue and a narrower loss versus the year-ago quarter: revenue was $11.8M and diluted EPS was $(0.03), with net loss of $0.52M compared with a $1.69M loss a year earlier.Financial HighlightsRevenue was $11.799M for Q1 2026, compared with $11.896M in the year-ago quarter; YoY change (0.8%).Net income (loss) was a loss of $0.524M for Q1 2026, compared with a loss of $1.686M in the year-ago quarter (loss narrowed).Diluted EPS was $(0.03) for Q1 2026, compared with $(0.10) in the year-ago quarter.Business HighlightsTotal revenues were essentially flat with glaucoma sales up 14.5% offset by a 12.3% decline in retina sales.U.S. and Germany sales are managed directly; international distribution is largely through Topcon and other distributors, with noted FX exposure on Euro-denominated sales.Continued adoption of MicroPulse® and Endpoint Management™ across glaucoma and retina product lines is driving recurring consumable probe revenue.Gross margin was pressured by higher manufacturing and tariff-related costs as the company shifts production toward lower-cost contract manufacturers.Management expects current cash to fund operations for at least 12 months and is focused on cost savings, R&D discipline, and preserving service and consumable revenue streams.Original SEC Filing: IRIDEX CORP [ IRIX ] - 10-Q - May. 19, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.